Dupilumab : a new treatment for severe T2 high asthma
Severe asthma often features a T2 high profile regulated by cytokines such as interleukins IL-4, IL-5 and IL-13. Dupilumab (Dupixent®) is humanized monoclonal antibody directed against the α subunit of the receptor for IL-4 and IL-13. Here we summarise the immunogical background of severe asthma which supports the use of dupilumab and the pivotal randomised controlled trials which have established the efficacy of dupilumab in treating people with severe asthma. Dupilumab reduces the exacerbation rate, has corticosteroids sparing effect, provides sustained improvement in expiratory flow rates and improved asthma control and quality of life with a reassuring safety profile. Dupilumab reduces the levels of FeNO values and of serum IgE but not those of circulating eosinophils. We also report on a few real life data with dupilumab supporting its clinical effectiveness.
| Medienart: |
Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:79 |
|---|---|
| Enthalten in: |
Revue medicale de Liege - 79(2024), 4 vom: 11. Apr., Seite 255-259 |
| Sprache: |
Französisch |
|---|
| Weiterer Titel: |
Dupilumab, Dupixent® :un nouveau traitement pour l’asthme sévère avec un profil «T2 high» |
|---|
| Beteiligte Personen: |
Louis, Renaud [VerfasserIn] |
|---|
| Anmerkungen: |
Date Completed 12.04.2024 Date Revised 12.04.2024 published: Print Citation Status MEDLINE |
|---|
| Förderinstitution / Projekttitel: |
|
|---|
| PPN (Katalog-ID): |
NLM370915356 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM370915356 | ||
| 003 | DE-627 | ||
| 005 | 20240412233639.0 | ||
| 007 | tu | ||
| 008 | 240411s2024 xx ||||| 00| ||fre c | ||
| 028 | 5 | 2 | |a pubmed24n1373.xml |
| 035 | |a (DE-627)NLM370915356 | ||
| 035 | |a (NLM)38602214 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a fre | ||
| 100 | 1 | |a Louis, Renaud |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Dupilumab |b a new treatment for severe T2 high asthma |
| 246 | 3 | 3 | |a Dupilumab, Dupixent® :un nouveau traitement pour l’asthme sévère avec un profil «T2 high» |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ohne Hilfsmittel zu benutzen |b n |2 rdamedia | ||
| 338 | |a Band |b nc |2 rdacarrier | ||
| 500 | |a Date Completed 12.04.2024 | ||
| 500 | |a Date Revised 12.04.2024 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Severe asthma often features a T2 high profile regulated by cytokines such as interleukins IL-4, IL-5 and IL-13. Dupilumab (Dupixent®) is humanized monoclonal antibody directed against the α subunit of the receptor for IL-4 and IL-13. Here we summarise the immunogical background of severe asthma which supports the use of dupilumab and the pivotal randomised controlled trials which have established the efficacy of dupilumab in treating people with severe asthma. Dupilumab reduces the exacerbation rate, has corticosteroids sparing effect, provides sustained improvement in expiratory flow rates and improved asthma control and quality of life with a reassuring safety profile. Dupilumab reduces the levels of FeNO values and of serum IgE but not those of circulating eosinophils. We also report on a few real life data with dupilumab supporting its clinical effectiveness | ||
| 650 | 4 | |a English Abstract | |
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Dupilumab | |
| 650 | 4 | |a IL-13 | |
| 650 | 4 | |a IL-4 | |
| 650 | 4 | |a Severe asthma | |
| 650 | 4 | |a T2 inflammation | |
| 650 | 7 | |a dupilumab |2 NLM | |
| 650 | 7 | |a 420K487FSG |2 NLM | |
| 650 | 7 | |a Interleukin-4 |2 NLM | |
| 650 | 7 | |a 207137-56-2 |2 NLM | |
| 650 | 7 | |a Antibodies, Monoclonal |2 NLM | |
| 650 | 7 | |a Interleukin-13 |2 NLM | |
| 650 | 7 | |a Anti-Asthmatic Agents |2 NLM | |
| 650 | 7 | |a Antibodies, Monoclonal, Humanized |2 NLM | |
| 700 | 1 | |a Sabbe, Mare |e verfasserin |4 aut | |
| 700 | 1 | |a Bougard, Nicolas |e verfasserin |4 aut | |
| 700 | 1 | |a Frix, Anne-Noëlle |e verfasserin |4 aut | |
| 700 | 1 | |a Schleich, Florence |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Revue medicale de Liege |d 1947 |g 79(2024), 4 vom: 11. Apr., Seite 255-259 |w (DE-627)NLM000044490 |x 0370-629X |7 nnns |
| 773 | 1 | 8 | |g volume:79 |g year:2024 |g number:4 |g day:11 |g month:04 |g pages:255-259 |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 79 |j 2024 |e 4 |b 11 |c 04 |h 255-259 | ||